Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma [Yahoo! Finance]
McKesson Corporation (MCK)
Last mckesson corporation earnings: 2/4 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.mckesson.com
Company Research
Source: Yahoo! Finance
–Safety and clinical outcomes support the therapeutic potential of VCN-01 in retinoblastoma and emphasize VCN-01's potential for use in diverse cancer indications– ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced positive topline data from the investigator sponsored Phase 1 trial conducted by collaborators at Sant Joan de Déu-Barcelona Children's Hospital (SJD). The Phase 1 trial was designed to evaluate the safety and tolerability of two intravitreal injections of Theriva's investigational oncolytic adenovirus VCN-01 in patients (n=9) with intraocular retinoblastoma that is refractory to chemotherapy or radiotherapy, and for whom enucleation was the only recommended treatment. “Results from the investigator sponsored trial further validate VCN-01's unique mechanism of action and therape
Show less
Read more
Impact Snapshot
Event Time:
MCK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCK alerts
High impacting McKesson Corporation news events
Weekly update
A roundup of the hottest topics
MCK
News
- McKesson (MCK) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Seeking Clues to McKesson (MCK) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics [Yahoo! Finance]Yahoo! Finance
- Virginia Cancer Specialists Continues to Increase Access to Care in New, Expanded Fair Oaks, VA, Location, Now Open [Yahoo! Finance]Yahoo! Finance
- Earnings Preview: McKesson (MCK) Q4 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- McKesson Co. (NYSE: MCK) had its price target raised by analysts at Citigroup Inc. from $575.00 to $620.00. They now have a "buy" rating on the stock.MarketBeat
MCK
Earnings
- 2/7/24 - Beat
MCK
Sec Filings
- 3/18/24 - Form 4
- 3/15/24 - Form 144
- 3/5/24 - Form 4
- MCK's page on the SEC website